$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000147929019000093 Filed on August 06, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$46.00K	$0.00	$686.0K
YoY Change	-98.05%	-100.0%	814.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$16.74M	$13.60M	$12.73M
YoY Change	18.26%	6.77%	47.91%
% of Gross Profit
Research & Development	$25.85M	$25.53M	$22.87M
YoY Change	18.3%	11.61%	24.93%
% of Gross Profit
Depreciation & Amortization	$730.0K	$790.0K	$420.0K
YoY Change	65.91%	88.1%	16.67%
% of Gross Profit
Operating Expenses	$42.59M	$39.12M	$35.61M
YoY Change	18.28%	9.88%	32.28%
Operating Profit	-$42.54M	-$39.12M	-$34.92M
YoY Change	26.45%	12.04%	30.1%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$130.0K	$115.0K	-$172.0K
YoY Change	-9.72%	-166.86%	30.3%
Pretax Income	-$41.41M	-$37.39M	-$34.08M
YoY Change	26.13%	9.71%	26.83%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$41.41M	-$37.39M	-$34.08M
YoY Change	26.12%	9.71%	26.81%
Net Earnings / Revenue	-90019.57%		-4967.93%
Basic Earnings Per Share
Diluted Earnings Per Share	-$956.1K	-$864.3K	-$925.1K
COMMON SHARES
Basic Shares Outstanding	44.10M shares	44.01M shares	36.78M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$209.0M	$241.9M	$233.7M
YoY Change	0.29%	3.51%	41.21%
Cash & Equivalents	$58.92M	$90.03M	$39.28M
Short-Term Investments	$150.1M	$151.9M	$194.5M
Other Short-Term Assets	$6.500M	$8.000M	$9.100M
YoY Change	-13.33%	-12.09%	3.41%
Inventory
Prepaid Expenses
Receivables	$5.000M	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$220.6M	$249.9M	$242.9M
YoY Change	2.17%	2.89%	39.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.92M	$15.26M	$12.20M
YoY Change	10.55%	25.15%	8.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.519M	$2.392M	$3.315M
YoY Change	-14.44%	-27.84%	273.31%
Total Long-Term Assets	$45.24M	$45.99M	$16.24M
YoY Change	163.55%	183.15%	27.65%
TOTAL ASSETS
Total Short-Term Assets	$220.6M	$249.9M	$242.9M
Total Long-Term Assets	$45.24M	$45.99M	$16.24M
Total Assets	$265.8M	$295.9M	$259.1M
YoY Change	14.06%	14.19%	38.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.902M	$7.966M	$5.435M
YoY Change	-5.98%	46.57%	33.24%
Accrued Expenses	$18.69M	$14.74M	$13.57M
YoY Change	18.93%	8.61%	-5.42%
Deferred Revenue	$5.241M	$18.83M
YoY Change	-40.1%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$34.15M	$44.70M	$28.32M
YoY Change	7.38%	57.8%	28.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$80.40M	$62.70M	$20.90M
YoY Change	320.94%	200.0%
Total Long-Term Liabilities	$80.40M	$62.70M	$20.90M
YoY Change	320.94%	200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.15M	$44.70M	$28.32M
Total Long-Term Liabilities	$80.40M	$62.70M	$20.90M
Total Liabilities	$114.5M	$107.4M	$49.27M
YoY Change	124.78%	117.89%	78.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$798.9M	-$757.5M	-$611.3M
YoY Change	24.02%	23.92%	28.53%
Common Stock	$950.1M	$945.9M	$821.4M
YoY Change	14.97%	15.16%	29.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$151.3M	$188.5M	$209.9M
YoY Change
Total Liabilities & Shareholders Equity	$265.8M	$295.9M	$259.1M
YoY Change	14.06%	14.19%	38.51%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$41.41M	-$37.39M	-$34.08M
YoY Change	26.12%	9.71%	26.81%
Depreciation, Depletion And Amortization	$730.0K	$790.0K	$420.0K
YoY Change	65.91%	88.1%	16.67%
Cash From Operating Activities	-$31.95M	-$29.29M	-$36.56M
YoY Change	25.74%	-19.89%	50.51%
INVESTING ACTIVITIES
Capital Expenditures	-$1.480M	-$380.0K	-$1.270M
YoY Change	-51.16%	-70.08%	4.96%
Acquisitions
YoY Change
Other Investing Activities	$2.400M	$54.39M	$5.100M
YoY Change	-92.81%	966.47%	-86.51%
Cash From Investing Activities	$920.0K	$54.01M	$3.830M
YoY Change	-96.97%	1310.18%	-89.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-80.00K	40.00K	2.940M
YoY Change	-108.89%	-98.64%	-6.96%
NET CHANGE
Cash From Operating Activities	-31.95M	-29.29M	-36.56M
Cash From Investing Activities	920.0K	54.01M	3.830M
Cash From Financing Activities	-80.00K	40.00K	2.940M
Net Change In Cash	-31.11M	24.76M	-29.79M
YoY Change	-631.79%	-183.12%	-292.69%
FREE CASH FLOW
Cash From Operating Activities	-$31.95M	-$29.29M	-$36.56M
Capital Expenditures	-$1.480M	-$380.0K	-$1.270M
Free Cash Flow	-$30.47M	-$28.91M	-$35.29M
YoY Change	36.15%	-18.08%	52.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36975203	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44105474	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36975203	shares
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36297
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0551645
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7555 Gateway Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newark
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94560
	dei	City Area Code CityAreaCode	510
	dei	Local Phone Number LocalPhoneNumber	742-3400
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	RVNC
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44102532	shares
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90034000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73256000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2392000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3247000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	151858000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	102556000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27000000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8013000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5110000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	249905000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	207922000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15263000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14449000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27602000	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	730000	USD
CY2019Q2	us-gaap	Assets Assets	295892000	USD
CY2018Q4	us-gaap	Assets Assets	226348000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7966000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8434000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14737000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14948000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18825000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8588000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3168000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44696000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31970000	USD
CY2019Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2824000	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2753000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32169000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42684000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27661000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3319000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	107350000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	80726000	USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	37000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	945851000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22871000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49521000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45111000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13596000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12734000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26506000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25526000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	830368000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	116000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-757469000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-684775000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	188542000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	145622000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	295892000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226348000	USD
CY2019Q2	us-gaap	Revenues Revenues	0	USD
CY2018Q2	us-gaap	Revenues Revenues	686000	USD
	us-gaap	Revenues Revenues	278000	USD
	us-gaap	Revenues Revenues	880000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26350000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	39122000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	35605000	USD
	us-gaap	Operating Expenses OperatingExpenses	76027000	USD
	us-gaap	Operating Expenses OperatingExpenses	71461000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-39122000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-34919000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-75749000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70581000	USD
CY2019Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1596000	USD
CY2018Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1081000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3166000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2103000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	44000	USD
CY2019Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	21000	USD
CY2018Q2	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-70000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-71000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-104000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	124000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-224000	USD
CY2019Q2	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-37390000	USD
CY2018Q2	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-34080000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-72694000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-69118000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.86
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37344000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34028000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72570000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69342000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	115000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-172000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-40000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-492000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37390000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-34080000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72694000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-69118000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	46000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.94
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43260317	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36123659	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42434137	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36037604	shares
CY2019Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	35166	shares
CY2018Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	18795	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	35166	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	18795	shares
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	387000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	438000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	387000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	439000	USD
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44105474	shares
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	188542000	USD
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36917723	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	209855000	USD
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44105474	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2903000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6970000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	188542000	USD
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36917723	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	209855000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72694000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-69118000	USD
	us-gaap	Depreciation Depreciation	1418000	USD
	us-gaap	Depreciation Depreciation	807000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1481000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	610000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8579000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8330000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	338000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	263000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27000000	USD
	rvnc	Increase Decreasein Operating Lease Rightof Use Assets IncreaseDecreaseinOperatingLeaseRightofUseAssets	2938000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-853000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2291000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-321000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-958000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-914000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1274000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-278000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24120000	USD
	rvnc	Increase Decreasein Operating Lease Liabilities IncreaseDecreaseinOperatingLeaseLiabilities	2637000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40704000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47701000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	164970000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	212197000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1466000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2335000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	117000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	18000000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	146000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49429000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196486000	USD
	rvnc	Proceeds From Issuanceof Follow On Offering Netof Commissionsand Discount ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount	108100000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	480000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3834000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1148000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1813000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	521000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	366000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	932000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106911000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	723000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16778000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-243464000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73986000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283476000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90764000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40012000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1408000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2128000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37400000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72700000	USD
CY2019Q2	rvnc	Working Capital Surplus WorkingCapitalSurplus	205200000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-757500000	USD
CY2019Q2	rvnc	Contractwith Customer Liability Net ContractwithCustomerLiabilityNet	241900000	USD
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></div>
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24700000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28200000	USD
CY2019Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	3500000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Medicis Settlement<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation (“Medicis”) entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of DAXI and DaxibotulinumtoxinA Topical from Medicis and for consideration payable by the Company to Medicis of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, comprised of (i) an upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0</span></span><span style="font-family:inherit;font-size:10pt;"> million, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0</span></span><span style="font-family:inherit;font-size:10pt;"> million due upon specified capital raising achievements by the Company, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$6.9</span></span><span style="font-family:inherit;font-size:10pt;"> million was paid in 2013 and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1</span></span><span style="font-family:inherit;font-size:10pt;"> million in 2014, and (iii) a product approval payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0</span></span><span style="font-family:inherit;font-size:10pt;"> million to be paid upon the achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical by the Company. In December 2012, Medicis was subsequently acquired by Valeant Pharmaceuticals International Inc., now known as Bausch Health Companies Inc. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and product approval payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.4 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.8%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the Company’s liability for the product approval payment was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 years</span></span><span style="font-family:inherit;font-size:10pt;">, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>2.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>8.0%</span></span><span style="font-family:inherit;font-size:10pt;">. The term is based on an expected Biologics License Application (“BLA”) approval in 2020. For the six months ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, no payment was made for the product approval payment.</span></div>
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	240455000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	116000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	240571000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	171784000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	240571000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	171776000	USD
CY2018	rvnc	Common Stock Outstanding Heldby Related Party CommonStockOutstandingHeldbyRelatedParty	3800000	shares
CY2018Q4	rvnc	Cash Cash Equivalentsand Investments Heldby Related Party CashCashEquivalentsandInvestmentsHeldbyRelatedParty	87700000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P14Y
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1425000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2768000	USD
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	298000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	588000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	1723000	USD
	us-gaap	Lease Cost LeaseCost	3356000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3268000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6735000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6942000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5464000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5557000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17959000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	45925000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	15096000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	30829000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5826000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6011000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6196000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4696000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	20173000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	42902000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3069000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3890000	USD
	rvnc	Indemnification Liability Recordedduring Period IndemnificationLiabilityRecordedduringPeriod	0	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4420000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4172000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8579000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8330000	USD
	rvnc	Increase Decreasein Deferred Tax Assets IncreaseDecreaseinDeferredTaxAssets	15000000	USD

Files In Submission

Name	View Source	Status
0001479290-19-000093-index-headers.html	Edgar Link	pending
0001479290-19-000093-index.html	Edgar Link	pending
0001479290-19-000093.txt	Edgar Link	pending
0001479290-19-000093-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20190630.xsd	Edgar Link	pending
rvnc-20190630_cal.xml	Edgar Link	unprocessable
rvnc-20190630_def.xml	Edgar Link	unprocessable
rvnc-20190630_lab.xml	Edgar Link	unprocessable
rvnc-20190630_pre.xml	Edgar Link	unprocessable
rvnc-q219exhibit311.htm	Edgar Link	pending
rvnc-q219exhibit312.htm	Edgar Link	pending
rvnc-q219exhibit321.htm	Edgar Link	pending
rvnc-q219exhibit322.htm	Edgar Link	pending
rvncq21910q.htm	Edgar Link	pending
rvncq21910q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2019 Q3 Form 10-Q Financial Statement

#000147929019000093 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2019 Q3 Form 10-Q Financial Statement

#000147929019000093 Filed on August 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc